Profile of adverse events (AE) based on initial dose of enzalutamide.

Figshare2021-10-01 更新2026-04-28 收录

数据链接：

https://figshare.com/articles/dataset/Profile_of_adverse_events_AE_based_on_initial_dose_of_enzalutamide_/16723728 数据链接链接失效反馈

官方服务：

资源简介：

Profile of adverse events (AE) based on initial dose of enzalutamide.

创建时间：

2021-10-01

Mean odds ratio (95% CrI) of AEs and discontinuation due to AEs.

药物安全性评估

不良事件分析

*Significant comparisons are in bold with an asterisk. Mean odds ratio (95% CrI) of AEs and discontinuation due to AEs.

NIAID Data Ecosystem100

fdata-02-00047_Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition.pdf

药物安全性评估

毒性测试

Ensuring the safety of new drugs is critically important to regulators, pharmaceutical researchers and patients alike. Even so, unexpected toxicities still account for 20–30% of clinical trial failure

NIAID Data Ecosystem30

Dataset from A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

前列腺癌治疗

临床疗效评估

The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for par

NIAID Data Ecosystem10

Pass rates calculated for the gamma evaluation in the tumor target and OARs compared with a reference TPS dose with the calculated dose in 3DVH and compass (C-Recal.: Compass Recalculation, C-Recon.: Compass Reconstruction) for the Prostate Plans.

放射治疗剂量验证

前列腺癌治疗

Pass rates calculated for the gamma evaluation in the tumor target and OARs compared with a reference TPS dose with the calculated dose in 3DVH and compass (C-Recal.: Compass Recalculation, C-Recon.:

NIAID Data Ecosystem60

DataSheet1_Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis.docx

结直肠癌临床研究

药物安全性评估

Objective: The occurrence, development, and prognosis of serious adverse events (SAEs) associated with anticancer drugs in clinical trials have important guiding significance for real-world clinical a

NIAID Data Ecosystem30

Profile of adverse events (AE) based on initial dose of enzalutamide.

资源简介：

相关数据集